Pharmacist Perspectives on High-Dose Methotrexate Management and Acute Kidney Injury Risk Mitigation in Patients With Lymphoma: Results From a National Survey
Journal of Pharmacy Practice · 2026
DOI: 10.1177/08971900261428900 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy Practice, 2026. Verfasst von Elizabeth B King und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Methotrexate, Lymphoma, Pharmacists, Acute Kidney Injury. Die Arbeit nennt 47 Literaturangaben. Gefördert von: Mayo Clinic Department of Pharmacy, CTSA, National Center for Advancing Translational Science.
Abstract (Originalsprache)
Background: A summary of pharmacist-based practices and preferences regarding the prevention and management of high-dose methotrexate (HDMTX) toxicity in patients with lymphoma does not exist. The objective of the study was to describe current practices surrounding management of HDMTX therapy. This was done through a self-administered, web-based, cross-sectional survey of hematology/oncology pharmacists to ascertain practices and individual attitudes about HDMTX therapy management. Responses were summarized with descriptive statistics. Response comparisons were made using Chi-square or Fisher’s exact test for categorical data, and Kruskal-Wallis test for variables on the Likert scale. A total of 175 pharmacists provided 116 eligible surveys [68 (59%) complete responses and 48 (41%) partial responses] for analysis. The Cockcroft-Gault estimated creatinine clearance formula was the most preferred method (61%) to estimate kidney function and determine HDMTX dosing. Respondents would proceed with HDMTX therapy until the predicted risk of AKI, or AKI stage 2 or 3, exceeded 50% and 20%, respectively. Preferred treatment modifications for a high predicted AKI risk after HDMTX exposure included additional prehydration, HDMTX dose reduction, and increased kidney function monitoring, although levels and degrees of agreement varied. Respondents indicated that serum cystatin C-based GFR estimates lacked evidence, accuracy, and practicality in HDMTX therapy management. There was limited familiarity with cell cycle arrest biomarker use during HDMTX therapy. Glucarpidase was considered time-sensitive and highly effective; however, acquisition cost represented a barrier to use, and the optimal dose was felt to be unknown. In conclusion, there is significant heterogeneity in supportive practices and beliefs about the optimal management for patients with lymphoma receiving HDMTX therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
- Department of Pharmacy, Cleveland Clinic, Cleveland, OH, USA.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
- Department of Pharmacy, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA.
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
- Division of Nephrology and Hypertension, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
ORCID-Profile: Elizabeth B King, Erin F Barreto
Förderung
- Mayo Clinic Department of Pharmacy
- CTSA
- National Center for Advancing Translational Science
- The National Institute Of Allergy And Infectious Diseases of the National Institutes of Health
Zitieren
APA
King, E. B., Rice, M. L., Truong, H. L., Cole, K. C., Barreto, E. F., Durani, U., Khurana, A., Herrmann, S. M., Leung, N., Witzig, T. E., & Barreto, J. N. (2026). Pharmacist Perspectives on High-Dose Methotrexate Management and Acute Kidney Injury Risk Mitigation in Patients With Lymphoma: Results From a National Survey. Journal of Pharmacy Practice. https://doi.org/10.1177/08971900261428900
Vancouver
King EB, Rice ML, Truong HL, Cole KC, Barreto EF, Durani U, et al. Pharmacist Perspectives on High-Dose Methotrexate Management and Acute Kidney Injury Risk Mitigation in Patients With Lymphoma: Results From a National Survey. Journal of Pharmacy Practice. 2026. doi:10.1177/08971900261428900
BibTeX
@article{King2026,
author = {King, Elizabeth B and Rice, Mikhaila L and Truong, Huong L and Cole, Kristin C and Barreto, Erin F and Durani, Urshila and Khurana, Arushi and Herrmann, Sandra M and Leung, Nelson and Witzig, Thomas E and Barreto, Jason N},
title = {Pharmacist Perspectives on High-Dose Methotrexate Management and Acute Kidney Injury Risk Mitigation in Patients With Lymphoma: Results From a National Survey},
journal = {Journal of Pharmacy Practice},
year = {2026},
doi = {10.1177/08971900261428900}
}
EUVIMED